JP7637988B2 - クロストリジウム・ディフィシルのワクチン組成物 - Google Patents

クロストリジウム・ディフィシルのワクチン組成物 Download PDF

Info

Publication number
JP7637988B2
JP7637988B2 JP2021568804A JP2021568804A JP7637988B2 JP 7637988 B2 JP7637988 B2 JP 7637988B2 JP 2021568804 A JP2021568804 A JP 2021568804A JP 2021568804 A JP2021568804 A JP 2021568804A JP 7637988 B2 JP7637988 B2 JP 7637988B2
Authority
JP
Japan
Prior art keywords
tcdb
holotoxin
gtd
immunogen
difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532917A (ja
JP2022532917A5 (https=
Inventor
ジン、ロンシェン
フェルナー、フィリップ
チェン、ペン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022532917A publication Critical patent/JP2022532917A/ja
Publication of JP2022532917A5 publication Critical patent/JP2022532917A5/ja
Application granted granted Critical
Publication of JP7637988B2 publication Critical patent/JP7637988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021568804A 2019-05-21 2020-05-21 クロストリジウム・ディフィシルのワクチン組成物 Active JP7637988B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851040P 2019-05-21 2019-05-21
US62/851,040 2019-05-21
PCT/US2020/034070 WO2020237090A1 (en) 2019-05-21 2020-05-21 Vaccine compositions for clostridium difficile

Publications (3)

Publication Number Publication Date
JP2022532917A JP2022532917A (ja) 2022-07-20
JP2022532917A5 JP2022532917A5 (https=) 2023-05-26
JP7637988B2 true JP7637988B2 (ja) 2025-03-03

Family

ID=73458679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021568804A Active JP7637988B2 (ja) 2019-05-21 2020-05-21 クロストリジウム・ディフィシルのワクチン組成物

Country Status (8)

Country Link
US (1) US20220062401A1 (https=)
EP (1) EP3972638A4 (https=)
JP (1) JP7637988B2 (https=)
CN (1) CN114126644A (https=)
BR (1) BR112021023119A2 (https=)
CA (1) CA3141165A1 (https=)
MX (3) MX2021014097A (https=)
WO (1) WO2020237090A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
EP4658302A1 (en) * 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516964A (ja) 2012-04-04 2015-06-18 ザ セクレタリー オブ ステート フォー ヘルスＴｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｓｔａｔｅ Ｆｏｒ Ｈｅａｌｔｈ クロストリジウム・ディフィシル抗原

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1000155A1 (en) * 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
WO2013084071A2 (en) * 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014086787A1 (en) * 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2015123767A1 (en) * 2014-02-18 2015-08-27 The Hospital For Sick Children Compositions and methods for treating or preventing clostridium infection
CA2976976C (en) * 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
WO2019143552A1 (en) * 2018-01-16 2019-07-25 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516964A (ja) 2012-04-04 2015-06-18 ザ セクレタリー オブ ステート フォー ヘルスＴｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｓｔａｔｅ Ｆｏｒ Ｈｅａｌｔｈ クロストリジウム・ディフィシル抗原

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEATHER K. KROH; ET AL，JOURNAL OF BIOLOGICAL CHEMISTRY，2018年01月19日，VOL:293, NR:3，PAGE(S):941 - 952，http://dx.doi.org/10.1074/jbc.M117.813428

Also Published As

Publication number Publication date
MX2026001280A (es) 2026-03-02
JP2022532917A (ja) 2022-07-20
MX2026001281A (es) 2026-03-02
EP3972638A4 (en) 2023-09-13
US20220062401A1 (en) 2022-03-03
EP3972638A1 (en) 2022-03-30
BR112021023119A2 (pt) 2022-01-25
WO2020237090A1 (en) 2020-11-26
CN114126644A (zh) 2022-03-01
MX2021014097A (es) 2022-03-11
CA3141165A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
Fagan et al. Structural insights into the molecular organization of the S‐layer from Clostridium difficile
Behrens et al. Pyocin S5 import into Pseudomonas aeruginosa reveals a generic mode of bacteriocin transport
Cullen et al. Outer membrane proteins of pathogenic spirochetes
Krupka et al. The position of his-tag in recombinant OspC and application of various adjuvants affects the intensity and quality of specific antibody response after immunization of experimental mice
Tao et al. A bivalent anthrax–plague vaccine that can protect against two tier-1 bioterror pathogens, Bacillus anthracis and Yersinia pestis
US20240139302A1 (en) Propionibacterium acnes prophylactic and therapeutic immune treatment
Vrentas et al. A diverse set of single-domain antibodies (VHHs) against the anthrax toxin lethal and edema factors provides a basis for construction of a bispecific agent that protects against anthrax infection
Wan et al. Flagella hook protein FlgE is a novel vaccine candidate of Pseudomonas aeruginosa identified by a genomic approach
JP7637988B2 (ja) クロストリジウム・ディフィシルのワクチン組成物
Hsieh et al. Extended low-resolution structure of a Leptospira antigen offers high bactericidal antibody accessibility amenable to vaccine design
Mirali et al. A two-protein cocktail elicits a protective immune response against Acinetobacter baumannii in a murine infection model
Craig et al. Multiple display of a protein domain on a bacterial polymeric scaffold
JP2024529044A (ja) レプトスピラ病毒性調節タンパク質とその使用
US12544441B2 (en) Compositions comprising CelTOS immunogens and antibodies and method of use thereof
Little The Type IV pilus secretin BfpB: structural analysis and binding interactions
Monaci Optimizing vaccine design for prevention of neonatal sepsis
HK40106181A (zh) 鈎端螺旋体毒力调节蛋白及其用途
WO2002083843A2 (en) Outer membrane associated polypeptides
Yao Quantitative Dissection of Molecular Driving Forces in Membrane Protein Folding
Li et al. Screening and structural characterization of a nanobody targeting the thermostable green fluorescent protein
Raghunathan et al. Human Factor H and anti-Neisserial surface protein A (NspA) antibodies compete for overlapping binding sites on meningococcal NspA
Islam et al. Rationally designed minimized TbpB confers broad protection against meningococcal infection
May Exploring the therapeutic potential of cell state specific binders to the β-barrel assembly machine
Perrotta Advancing technology platforms for the development of bacterial vaccines
Mouhib Native incorporation of outer membrane proteins into vesicles suitable for high resolution NMR spectroscopy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250210

R150 Certificate of patent or registration of utility model

Ref document number: 7637988

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150